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Mitochondrial protein translation is a complex process performed within mitochondria by an apparatus composed of
mitochondrial DNA (mtDNA)–encoded RNAs and nuclear DNA–encoded proteins. Although the latter by far outnumber
the former, the vast majority of mitochondrial translation defects in humans have been associated with mutations in
RNA-encoding mtDNA genes, whereas mutations in protein-encoding nuclear genes have been identified in a handful
of cases. Genetic investigation involving patients with defective mitochondrial translation led us to the discovery of
novel mutations in the mitochondrial elongation factor G1 (EFG1) in one affected baby and, for the first time, in the
mitochondrial elongation factor Tu (EFTu) in another one. Both patients were affected by severe lactic acidosis and rapidly
progressive, fatal encephalopathy. The EFG1-mutant patient had early-onset Leigh syndrome, whereas the EFTu-mutant
patient had severe infantile macrocystic leukodystrophy with micropolygyria. Structural modeling enabled us to make
predictions about the effects of the mutations at the molecular level. Yeast and mammalian cell systems proved the
pathogenic role of the mutant alleles by functional complementation in vivo. Nuclear-gene abnormalities causing mi-
tochondrial translation defects represent a new, potentially broad field of mitochondrial medicine. Investigation of these
defects is important to expand the molecular characterization of mitochondrial disorders and also may contribute to
the elucidation of the complex control mechanisms, which regulate this fundamental pathway of mtDNA homeostasis.
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The mitochondrial respiratory chain (MRC) is a multi-
heteromeric enzymatic structure that performs oxidative
phosphorylation (OXPHOS), a fundamental reaction of
life that supplies ∼90% of the energy used by mammalian
cells.1 The MRC consists of five complexes, composed of
∼85 structural proteins, 13 of which are encoded by
mtDNA, whereas the others are encoded by nuclear genes.
The 13 mtDNA-encoded polypeptides (designated “mit”
genes, according to the yeast mtDNA terminology) are
integral parts of four MRC complexes; seven are subunits
of complex I (cI), one is a subunit of complex III (cIII),
three are subunits of complex IV (cIV, or cytochrome c
oxidase [COX]), and two are subunits of complex V (cV).
Complex II (cII, or succinate:ubiquinone oxidoreductase)
is the only MRC complex that lacks mtDNA-encoded sub-
units. The mit genes are translated into proteins within
the organelles by a protein-synthesis machinery, com-
posed of both RNAs and proteins, which is largely inde-
pendent from that responsible for translation of genes
contained in the nuclear genome, which takes place in
the cytosol. The RNA component of mitochondrial trans-
lation consists of 22 tRNAs and 2 ribosomal RNAs (rRNAs)
encoded by mtDNA genes (designated “syn” genes, ac-
cording to the yeast terminology), whereas the protein
component is encoded by nuclear genes and consists of
∼50 ribosomal proteins; several tRNA maturation en-
zymes; the aminoacyl-tRNA synthetases; the translation
initiation, elongation, and termination factors; and likely
a large number of unidentified factors, including ribo-
some-assembly factors.2,3 Abnormalities in either gene
set—mitochondrial or nuclear—can compromise mito-
chondrial translation; as a consequence, multiple bio-
chemical defects may occur in the mtDNA-dependent
MRC complexes, leading to faulty OXPHOS and disease.
Over 100 disease-causing mutations are known in either
tRNA- or rRNA-encoding mtDNA syn genes (Mitomap). In
contrast, only a few patients have been reported with mu-
tations in mitochondrial translation protein factors. More
precisely, a missense mutation in pseudouridine synthase
1 (PUS1) was identified in Persian Jewish families affected
by myopathy, lactic acidosis, and sideroblastic anemia
(MLASA [MIM #600462]). PUS1 converts uridine into
pseudouridine in several positions of tRNAs synthesized
in both nuclear and mitochondrial compartments4,5; lack
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Figure 1. Brain MRIs of patient I.V. (A and B) and patient S.S.
(C and D). A, T2-weighted coronal section showing hyperintense
symmetric lesions of the putamen and globus pallidus (arrow).
B, T1-weighted image of the same section as in panel A, showing
hypointense abnormal signals (arrow) corresponding to those
shown in A. C, T2-weighted coronal section showing diffuse hy-
perintensity of the centra semiovalia and basal ganglia. The arrow
indicates an area of micropolygyria in the right perisylvian region.
D, T2-weighted coronal section showing diffuse hyperintensity and
multiple cysts of the white matter.
of this posttranscriptional maturation of tRNAs leads to
defective cytosolic and mitochondrial translation. A sec-
ond observation concerned a homozygous stop mutation
in MRPS16 (MIM *609204), a protein of the mitochondrial
small ribosomal subunit, which was found in one infant
with severe lactic acidosis, developmental defects in the
brain, and facial dysmorphisms.6 A missense mutation in
the mitochondrial elongation factor G1 (EFG1) was found
in a singleton case affected by fatal neonatal liver failure
and lactic acidosis associated with severe mitochondrial
translation defect (combined oxidative phosphorylation
deficiency 1 [MIM #609060]).7 Combined nonsense and
missense mutations in the same gene were later found in
two compound heterozygous brothers with a similar syn-
drome.8 Finally, the same homozygous missense mutation
in the mitochondrial translation elongation factor Ts
(EFTs) has recently been reported in two unrelated babies,
one affected by mitochondrial encephalomyopathy, the
other by fatal hypertrophic cardiomyopathy.9 However,
since nearly 200 nuclear-encoded proteins participate in
the translation of mitochondrial transcripts, it is reason-
able to assume that defects in these proteins are either
lethal or are underdiagnosed to a major extent.
We report here the results of a study involving two un-
related infants affected by neonatal lactic acidosis, rapidly
progressive encephalopathy, severely decreased mito-
chondrial protein synthesis, and combined deficiency of
mtDNA-related MRC complexes. One patient carried two
novel allelic mutations in the elongation factor EFG1; the
other is the first patient harboring a homozygous muta-
tion in the elongation factor Tu (EFTu).
Case Reports
Patient I.V.
Patient I.V. was the second daughter of Italian, noncon-
sanguineous, unaffected parents. The patient was born at
term after an uneventful pregnancy. The mother had pre-
viously had a spontaneous early miscarriage. Family his-
tory was negative for neurological disease. The patient’s
14-year-old sister is alive and well.
At birth, the baby had the following measurements:
weight 3,300 g, body length 49 cm, head circumference
35 cm. At age 7 d, she was evaluated for the presence of
dysmorphic signs, including flat nasal bridge, low-set ears,
small hands and feet, epicanthus, and high, arched pal-
ate. A total-body radiograph showed short tibial bones,
whereas the results of brain and kidney ultrasound, thy-
roid hormone levels, electrocardiogram (ECG), and fundus
oculi were normal. At age 3 wk, the patient started having
feeding difficulties and gain loss. The karyotype was
46,XX, with no chromosomal abnormalities.
At age 3 mo, the neurological examination showed re-
duced spontaneous movements and severe axial hypo-
tonia, with preservation of deep tendon reflexes. Blood
creatine kinase, transaminases, lactate dehydrogenase,
and ammonia levels were normal. The ECG remained nor-
mal, but an electroencephalogram showed global, severe
disorganization with complete lack of sleep spindles.
At age 5 mo, she presented with recurrent episodes of
vomiting. Plasma and urinary amino acids were normal,
as were plasma carnitine, mucopolysaccharides, and long-
chain fatty acids. Urine organic-acids analysis showed in-
creased lactic and b-hydroxybutyrate. Blood lactic acid was
5.2 mM (normal values [nv] !2.2), blood pyruvate was 0.46
mM ( ), and blood b-hydroxybutyrate was 0.39 mMnv ! 0.2
( ). The combined increase of both lactate and py-nv ! 0.1
ruvate suggests the presence of a very severe retrograde
block of glucose utilization in this patient.
Brain magnetic resonance imaging (MRI) showed two
large, bilateral and symmetrical areas of increased T2 (fig.
1A) and decreased T1 signals (fig. 1B) involving the pu-
tamen and the globus pallidus. Similar signal changes were
detected in the rostral mesencephalon, and there was de-
layed frontal myelination.
The patient was given treatment with ubidecarenone,
riboflavin, and thiamine; feeding problems were addressed
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Table 1. PCR Primers and Annealing Temperatures Specific to Human EFG1
and EFTu Genes
Gene
and Exons
Primer Sequence
(5′r3′)
Annealing
Temperature
(C)Forward Reverse
EFG1a:
1 CCTCACTCTCTTTTTCCTCGC CCCAGAAGGGATCACAAGGT 54
2 GGTGCCTTTCTCAAGCTATCT TCAAAAGTCCGCTGTTACCATTG 55
3 TCTTGGAATGCAGGGACAGAG GCTCTAGGTCCTAAGTTAGTCT 54
4 GACTTATGTGATGAGCAGAGATA GGATATAAGGTTTGCTGTCTAGA 54
5 CAAAGGGATTAGGGGAGAAGA AGATAGTTACTCTGCGTTTGATGA 55
6 ATGTATCAGAGCTCTTTGTTACC ATAAAAGCATCATGTCCCCTCCC 56
7 GTTGACTTGAAGCACAACATG TCCTTAAATTCCTTCACAGTGCA 53
8 ACTTATTGTGTGACAGCAGTAATATCC GAACTATCATGTCAGAGCTTTGGA 55
9 CTTGGAGGGAGTTATGAAGCT CTATTTCACCCACATCAGAGGAAT 55
10 CAATGTGTGTACTGTACAGTTTAC CTCAACGAAAACTTCTGTGGTTGT 55
11 GTCTAGCCTAAAGACATAGGC ACCAACAGAGGAAATAGAGACC 55
12 TCCCATTGCTTATCATGCTCAG GTGACGCATGAAGAACCAGAG 56
13 GCTTAGGAGGTTTTCTTTCGG CAGTAATAGTGGTATGTATATCCA 55
14 TTACCTTGGGTAGTATACCCCA GTGATAGACAACATGATGGAAG 55
15 GGGGTTCTTGATAATGTATCTGC TGAGGCTATGATGATCTATCAGG 54
16 GTGTTTGTACCTTTGGAAAGCAT TCAGCAAGGAAATGTGTCCATTTG 56
17/18 AGGCTGTCAATGGTGTTCACT CGCAGATTCAATTAGAGTCAGTC 55
EFTub:
1/2 AGCTCTAACTTCCGCCGGAA TCCAGGTCCCATCAGTAGATA 55
3 TGCCTCTAGCACTGGAACTT TCCTGACAAGAGGCAGCTTCT 55
4/5 GTGAACTGAAGAGCTCGTTG AGACACAAAGCAGAGCTCTG 55
6/7 CAGAGCTCTGCTTTGTGTCT AGAGGGAAGGCACAAGGGA 55
8/9 TCCCTTGTGCCTTCCCTCT GGAACTATGAGTGAAGCAAAGG 56
10 TTAAGGAATGAAGGCACCCTGG TCCTCCCCTATCCTCTCCAAT 56
a NCBI accession number NM_024996.
b NCBI accession number NM_003321.
with nasogastric feeding. Nevertheless, her weight at age
14 mo was 7,530 g, well below the 3rd percentile. The
hepatic enzymes, bilirubin, and ammonia remained con-
sistently normal in the blood during the entire course of
her life, and no sign of liver involvement was ever de-
tected. However, she had microcephalia, severely delayed
motor and mental development, decreased axial and
increased limb muscle tone, brisk deep-tendon reflexes,
and purposeless movements. Lactic acid was persistently
high. At age 16 mo, the patient died from a respiratory
insufficiency. The family declined to have an autopsy
performed.
Patient S.S.
Patient S.S. was the second daughter of reportedly non-
consanguineous, unaffected parents, originating from a
small village in an isolated valley of Italian South Tyrol.
She was born at term after an uneventful pregnancy. Fam-
ily history was negative for neurological disease. Her 20-
year-old brother is alive and well. The karyotype was
46,XX, with no abnormalities.
At birth, the baby had the following measurements:
weight 2,770 g, body length 48 cm, and head circumfer-
ence 31 cm. At 2 d after birth, she developed acute re-
spiratory distress and severe metabolic acidosis (pH 7.2;
PCO2 15 mmHg; PO2 60 mmHg; O2 saturation 90%; base
excess 26 mM), with two episodes of generalized hy-
pertonus and opisthotonus. Serum lactic acid was 10.2
mM ( mM). A brain CT scan showed several hy-nv ! 2.2
podense lesions in the right parietal and bilateral peri-
ventricular regions. The patient had occasionally high se-
rum ammonia (143 mg/dl; mg/dl) and mildlynv ! 75
elevated serum transaminases (serum glutamic oxaloacetic
transaminase 106 U/liter; U/liter; serum glutamicnv ! 42
pyruvic transaminase 51 U/liter; U/liter). ECGnv ! 38
showed signs of myocardial ischemia. The lactic acidosis
was partially corrected by intravenously administered bi-
carbonate. She was relatively well until age 6 mo, when
she had another episode of severe metabolic crisis, char-
acterized by persistent vomiting, lethargy, skin pallor, and
acral cyanosis, because of acute metabolic acidosis (pH
7.04; PCO2 24.1 mmHg; PO2 46.7 mmHg; base excess
24.2 mM). Serum lactate was 86 mM, ammonia was 89
mg/dl. In the following weeks, several episodes of acute
metabolic acidosis were corrected by intravenous admin-
istration of bicarbonate. The acute episodes punctuated a
relentless downhill course characterized by severe psy-
chomotor regression with microcephaly, generalized axial
hypotonia with limb spasticity, and nystagmus. The liver
was enlarged. Brain MRI at age 8 mo showed the presence
of micropolygyria in the right perisylvian region and dif-
fuse signal abnormality of the white matter in the centra
semiovalia, putamina, and nuclei pallidi (fig. 1C), with
multiple cystic lesions (fig. 1D); marked alterations of the
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Figure 2. mtDNA-specific protein synthesis on fibroblasts from
a control, patient S.S., and patient I.V. The autoradiographic bands
are labeled according to standard nomenclature: ND1, ND2, ND3,
ND4, ND4L, ND5, and ND6 are subunits of cI; Cyt b is cytochrome
b, a subunit of cIII; COI, COII, and COIII are subunits of cIV; and
A6 and A8 are subunits of cV.
Table 2. Yeast Strains
Strain Genotype Source
BY4741Dmef1 MATa; his3D1 leu2D0 lys2D0 ura3D0; YLR069c::kanMX4 Euroscarf collection
BY4741Dtuf1mef1BY4741Dmef1 MATa; his3D1 leu2D0 lys2D0 ura3D0; YOR187w::kanMX4 Euroscarf collection
W303-1B MATa ade2 his3 leu2 trp1 ura3 R. Rothstein collection
TUW Cross of BY4741 Dtuf1 and W303-1B Present study
MEW Cross of BY4741 Dmef1 and W303-1B Present study
EB-4B MATa ade2 his3 leu2 trp1 ura3 MIP1::kanMX4 sml1::HIS3 r0 I. Ferrero collection
white matter were also present in the brain stem and,
although to a lesser extent, in the cerebellum (not shown).
The patient died at age 14 mo. The family declined to
have an autopsy performed.
Material and Methods
Patients and DNA Samples
We obtained institutional review board–approved informed con-
sent from parents of all probands and siblings before collecting
blood for DNA extraction or performing tissue biopsies.
Sequence Analysis
Nucleotide sequence analysis was performed on a 3100 ABI Au-
tomated Sequencer on samples prepared using the BigDye Ter-
mination kit (Applied Biosystems). Data were elaborated using
the Secscape software (Applied Biosystems). The oligonucleotide
primers used for PCR amplification of the 18 exons of the human
EFG1 (NCBI accession number NM_024996) and the 10 exons
of the human EFTu encoding TUFM (NCBI accession number
NM_003321) genes are listed in table 1. PCR amplification con-
ditions were as follows: an initial denaturation step at 95C for
1 min; 30 cycles of denaturation at 95C for 1 min, annealing at
different temperatures (depending on the primers used; table 1)
for 30 s, and extension at 72C for 1 min; and a final extension
at 72C for 5 min.
Generation and Cloning of Human Mitochondrial EFG1
and EFTu
The full-length human IMAGE cDNA clones for Homo sapiens
EFG1 and EFTu were obtained from the RZPD German Re-
source Center (EFG1 clone IRATp970B0374D; EFTu clone
IRAUp969C0361D). The two cDNA inserts were amplified using
the following primers: for EFG1, forward primer 5′-CACCCGTTA-
CCGGCAGCTGAACC-3′ and reverse primer 5′-CAAAACCACG-
CAGATTCAATTAGAGTC-3′ and, for EFTu, forward primer 5′-
CACCCTGTGCGCTCGGGCTCCTGG-3′ and reverse primer 5′-
AGCCCTGGCTAGGGCAGGCCTTAAAC-3 ′ (the underlined
sequence at 5′ end of the forward primers is added to provide a
sticky ends necessary for directional cloning). The PCR products
were then cloned into the pcDNA3.2/V5/GW/D-TOPO vector (In-
vitrogen). The recombinant plasmids were transfected by elec-
troporation in patients’ fibroblasts, as described elsewhere,10 and
were selected with 200 mg/ml of the neomycin analogue drug
G418. For retrotranscription of EFTu RNA, the AMV kit cDNA
(Invitrogen) was used in accordance with the manufacturer’s
protocol.
Mammalian Cell Cultures
Mammalian cells were cultured in Dulbecco’s modified Eagle me-
dium (DMEM) (4.5 g/liter glucose), supplemented with 0.1 mM
of Na pyruvate, 50 mg/ml uridine, 200 U/ml penicillin/strepto-
mycin, 2 mM glutamine, and 10% fetal calf serum, at 37C in a
5%-CO2 atmosphere. Selection in galactose was performed using
medium containing DMEM (without glucose), 25 mM galactose,
10% dyalized calf serum, 200 U/ml penicillin/streptomycin, and
2 mM glutamine.
Patients’ fibroblasts were transfected, with plasmid pBABE car-
rying resistance to puromycin,11 whereas 143B r cells were trans-
fected with plasmid pRNS-1 carrying resistance to G418.11 Pa-
tients’ fibroblasts and 143B r cells were cocultured overnight,
were fused with a solution of poly-ethylene glycol in phosphate
buffer, and were selected, after 24 h, in a medium containing 200
mg/ml of G418 and 0.5 mg/ml of puromycin.11
Biochemical assays were performed after 2 wk of selection,
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Table 3. Oligonucleotides Used for Site-Directed Mutagenesis and for Cloning
and Sequencing
Oligonucleotide Use and
Name
Sequence
(5′r3′)
Amino Acid
Change
Site-directed mutagenesisa:
MEF1for AAAGAAACAATTATTTCTGGGAGAGGTGAATTGCATCTGGAGATT M516R
MEF1rev AATCTCCAGATGCAATTCACCTCTCCCAGAAATAATTGTTTCTTT
TUF1for TCAGGAGAGATCAATTGAAGCAAGGTATGGTCTTAGCTAAGCCA R325Q
TUF1rev TGGCTTAGCTAAGACCATACCTTGCTTCAATTGATCTCTCCTGAT
Cloning and sequencingb:
MEF1for ATCGGAATTCTTGAGGGCCCGGAATGAAG
MEF1rev ATCGGCATGCTATGCCGTACCAGAAAAGGAAC
MEF1seq1 GTCTGCCGCTACTTACTGCTCT
MEF1seq2 CCTAATCCCTCTGAAGTGTTGAAT
MEF1seq3 AGAATCCACGGCATGAATAGCAC
TUF1for AGGATCCCTTCATCGCCTGCTTACTACTTTG
TUF1rev AGCATGCACGCCTTTAACTTTCTCCCGACTA
TUF1seq1 TTTAGCACCCATCCGACCTCAGT
TUF1seq2 GTTAGCCGCAAAAGGTGGTG
TUF1seq3 CTGGTCGTGTGGAAAGGGGTAAT
a Base changes are underlined.
b Sequences in italic at the 5′ end of the primer have been added to provide the ends necessary for cloning.
Table 4. MRC Activities of cI–cV on Homogenate,
Normalized to the Activity of Citrate Synthase (CS)
Tissue
and Patient cI cII cIII cIV cV CS
Muscle:
I.V. 10 25 ND 53 ND 210
S.S. 5 26 90 23 197 91
Normal 17–31 23–39 110–200 100–160 140–250 90–190
Fibroblasts:
I.V. 4 17 58 17 35 109
S.S. 10 17 127 25 76 131
Normal 14–34 16–38 120–240 85–150 75–145 50–120
NOTE.—Data are calculated as nmol/min/mg protein. NDp not done;
Normal p normal range.
when both parental cells and homodicaryon hybrids, grown in
the selection medium, were completely eliminated. Characteri-
zation of the nuclear DNA in the resulting heterodikaryons was
performed using a highly polymorphic repetitive sequence at the
D11S533 locus, as described elsewhere.12
Western-Blot Analysis
Mitochondria were isolated from cultured fibroblasts as described
elsewhere.13 Analysis by SDS-polyacrylamide gel of 100 mg
protein/lane and western-blot analysis were performed as de-
scribed elsewhere,14 by use of the ECL-chemiluminescence kit
(Amersham).
Antibodies
An affinity purified polyclonal anti-mammalian EFTuEFTs an-
tibody15 was a kind gift of Professor Linda Spremulli (University
of North Carolina at Chapel Hill). A mouse monoclonal antibody
against the 70-kDa subunit of mammalian succinate dehydro-
genase was from Molecular Probes–Invitrogen.
Biochemical and Histochemical Assays
Specific activities of individual respiratory chain complexes were
measured on cell and muscle homogenates.16 Protein concentra-
tion was measured by the Folin-Ciocalteau method.17 Specific ac-
tivities of each complex were normalized to that of citrate syn-
thase,16 an indicator of the number of mitochondria.
Cytochrome c oxidase activity was visualized cytochemically
in cell culture grown on a coverslip, washed twice in PBS con-
taining 1 mg/ml MgCl2 and 1 mg/ml CaCl2, and air dried. Cells
were preincubated for 15 min at room temperature in a buffer
containing 50 mM Tris-HCl (pH 7.6), 1.2 mM CoCl2, and 10%
sucrose. They were rinsed once in 10% sucrose and 0.1-M Na
phosphate (pH 7.6) and were incubated for 1–2 h at 37C in 0.1-
M Na phosphate buffer (pH 7.6), containing 2 mg/ml of cyto-
chrome c, 1 mg/ml diaminobenzidine tetrahydrochloride, and
0.2 mg/ml catalase. Cells were rinsed once in 0.1-M Na phosphate
buffer (pH 7.6) and 10% sucrose, once in PBS-Mg-CaCl2, and once
in distilled water. Coverslips were mounted in 50% glycerol-PBS
and were visualized under a light microscope (NIKON Eclipse
E400).
In Vivo Mitochondrial Translation Assay
Analysis of mitochondrial protein synthesis was performed fol-
lowing the protocol by Chomyn.18 Cells at 70% confluence were
labeled for 2 h with [35S]-methionine-cysteine in the presence of
100 mg/ml emetine, an inhibitor of cytosolic protein synthesis.
Samples were kept at 80C until use. Equal amount of total
cellular protein17 were loaded on a 20% to 15% exponential gra-
dient of polyacrylamide gel. The gel was then fixed and dried,
and the mitochondrial translation products were visualized and
measured densitometrically by a PhosphorImager apparatus
(BioRad) by use of the Quantity One software provided by the
manufacturer.
Homology Modeling
Each protein model was built using the automatic homology
modeling server SWISS-MODEL.19 The model of EFTu was built
www.ajhg.org The American Journal of Human Genetics Volume 80 January 2007 49
Figure 3. Light-microscopy examination of a muscle biopsy spec-
imen from patient I.V. A, Modified Gomori trichrome staining. B,
Succinate dehydrogenase (SDH) reaction. C, Cytochrome c oxidase
(COX) reaction. D, SDH and COX reaction.
using the coordinates of the crystal structure of EFTu from Bos
taurus (Protein Data Bank [PDB] 1D2E), which shows 96% se-
quence identity with the human homolog. Whatcheck20 analysis
confirmed the quality of the model.
The EFG model was built using the protein crystal structure
from Thermus thermophilus (PDB 2BM0) that shares 40% of resi-
dues identical to the human sequence. Despite the relatively low
sequence identity, this protein contains four highly conserved
domains that make it a suitable homology-modeling target. In
fact, the Whatcheck report shows that the overall model quality
is only slightly lower in comparison to the EFTu model.
Structural analysis was made using VMD,21 and secondary struc-
ture content was assigned by STRIDE.22
Yeast Strains, Media, and General Genetic Methods
Yeast strains are listed in table 2. Cells were cultured in YP (1%
Bacto-yeast extract and 2% Bacto-peptone) or YNB medium
(0.67% yeast nitrogen base without amino acids [Difco]), supple-
mented with the appropriate amino acids and bases for auxotro-
phy, at a final concentration of 40 mg/ml. Media were solidified
with 20 g/liter agar. Glucose and ethanol were added at 2% (w/
v), and glycerol at 3% (v/v). For the cytochrome absorption spec-
tra, cells were grown to late-log phase in YNB medium supple-
mented with 0.5% glucose. Genetic procedures for crossing,
sporulation, and tetrad dissection were performed by a standard
protocol.23 To obtain a heterozygous diploid MEF1/Dmef1 strain,
a Dmef1 petite mutant strain was crossed with the wild-type strain
W303-1B.
Construction of Yeast Mutant Alleles
MEF1M516R and TUF1R328Q mutant alleles were produced by site-
directed mutagenesis, by use of the QuikChange Kit (STRATA-
GENE). MEF1 and TUF1 wild-type genes cloned in pUC19 vector
were used as template DNA. To obtain these plasmids, we PCR
amplified DNA fragments of 3,018 bp (MEF1) and 2,596 bp
(TUF1),24 containing the ORFs and the 5′ and 3′ flanking regions
(respectively, 629 bp and 653 for TUF1 and 242 and 490 bp for
MEF1), using genomic DNA of strain BY4741 as template and the
appropriate forward and reverse primers containing restriction
sites at their 5′ ends. To maximize the expression of the mutant
allele, the preferred yeast codon encoding for either glutamine
(CAA) or arginine (AGA) was used in the oligonucleotide se-
quences used for mutagenesis. Both wild-type and mutagenized
inserts for each different construct were cloned in the pFL38 cen-
tromeric plasmid vector and sequence-verified on both strands.
The sequences of the oligonucleotides used for cloning and se-
quencing MEF1, the base changes, and the corresponding mod-
ified primers used to generate mutated alleles are reported in ta-
ble 3.
Southern-Blot Analysis in Yeast Strains
mtDNA was extracted by rapid mitochondrial preparation25 from
cells grown in YNB supplemented with 2% glucose. Aliquots of
1 mg of DNA were digested with EcoRV (Amersham). Southern-
blot analysis was performed as described elsewhere.26 Hybridi-
zation was performed by standard methods, with a 5′-[g-32P]ATP
end-labeled yeast mtDNA-specific sequence repeat as a probe: 5′-
CTCCTTTCGGGGTTCCGGCTCCCGTGGCCGGGCCCCGG-3′.
Miscellaneous Yeast Methods
Transformation of yeast strain was obtained by the lithium-
acetate method.27 Restriction-enzyme digestions, Escherichia coli
transformation, and plasmid extractions were performed using
standard methods.28 Cytochrome spectra were determined as de-
scribed elsewhere.26
Statistics
Two-tailed, unpaired Student’s t test was used to calculate the
significance of biochemical and molecular data. Statistical anal-
ysis was performed when four or more values were available for
each category.
Results
Biochemical Assays and Mitochondrial Protein Synthesis
Multiple defects of mtDNA-dependent MRC complexes,
particularly cI and cIV, were detected in the homogenates
from muscle biopsies and skin-derived fibroblasts (table 4)
taken at age 8 mo in both patients. The mtDNA-specific
protein synthesis was severely reduced in fibroblasts from
both patient I.V. and patient S.S., compared with control
fibroblasts. Additional bands, which could not be attrib-
uted to a specific mtDNA protein species, were present in
the high-molecular-weight range of both patients (fig. 2).
The decrease varied for individual protein species—for in-
stance, densitometric comparison between patients and
controls gave a mean reduction of 87% for COX-I in both
patients; of 74% and almost 95% for ND2 in patients I.V.
and S.S., respectively; and of 70% and 88% for A6 in pa-
tients S.S. and I.V., respectively. ND1 was virtually unde-
tectable in both patients.
Light-microscopy examination of the muscle biopsy
specimen from patient I.V. showed diffusely increased fuc-
sinophilia at the modified trichrome Gomori stain, with
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Figure 4. Molecular characterization of EFG1 and EFTu mutations. Below the sequencing profiles of EFG1 and EFTu genes in patients
I.V. and S.S. are the ClustalW interspecies alignments of protein sequences from H. sapiens (Human), Mus musculus (Mouse), Drosophila
melanogaster, Caenorhabditis elegans, and S. cerevisiae (Yeast). The mutant nucleotides are in yellow-shaded circles, and the mutant
amino acid residues are labeled in red. Western blotting shows the presence of both EFTu and EFTs proteins in patient S.S. The 70-kDa
succinate dehydrogenase (SDH) band was immunovisualized as a control.
mildly increased content of lipid and glycogen. Histo-
chemically, the reaction specific to succinate dehydroge-
nase (part of cII), an MRC complex that does not contain
mtDNA-encoded subunits, was increased, whereas the
reaction specific to COX, which contains three mtDNA-
encoded subunits, was reduced but not absent (fig. 3).
Morphological analysis was not performed on the muscle
biopsy sample from patient S.S.
Genetic Screening and Protein Western-Blot Analysis
Sequence analysis of the entire mtDNA from muscle of
both patients failed to reveal mutations in either syn or
mit genes, thus ruling out mtDNA as the disease-respon-
sible genome. Since mitochondrial protein synthesis was
severely impaired in both patients, we set up a candidate-
gene strategy based on the screening of factors involved
in mitochondrial translation. We first analyzed three
genes in which mutations were already reported—namely,
those encoding PUS1, EFG1, and MRPS16. In patient I.V.,
both PUS1 and MRPS16 sequences were normal, but we
found two mutations in EFG1, a CrT transition at nucle-
otide position (np) 139 of the cDNA that causes the re-
placement of the amino acid residue R47 with a stop co-
don (TGA), and a TrG transversion at np 1478 that causes
an M496R amino acid change (fig. 4). A heterozygous
R47X was detected in the patient’s father, whereas a het-
erozygous M496R was detected in the mother, thus prov-
ing that the mutations were allelic in the patient. The
sister was heterozygous for the latter mutation.
No mutation in the above genes was found in patient
S.S. Since her clinical presentation had features in com-
mon with that of I.V., including early onset, severe lactic
acidosis, and predominant involvement of the CNS, we
expanded the analysis to genes encoding two additional
mitochondrial protein elongation factors—namely, EFTu
and its auxiliary recycling factor, EFTs. No mutation was
found in the EFTs, but a homozygous missense mutation
was detected in EFTu. As shown in figure 4, this mutation,
a GrA transition at np 1016 of the cDNA, converts the R
residue at position 339 into a Q residue (R339Q). Both
parents and the patient’s brother were heterozygous for
the mutation.
Western-blot analysis with the use of a specific antibody
showed that the amount of EFTu protein detected in pa-
tient’s skin fibroblasts was comparable to that in control
fibroblasts (fig. 4). Neither mutation was found in DNA
samples from 100 consecutive Italian control individuals.
Structural Modeling of Mutant EFG1M496R and EFTuR339Q
Proteins
To make predictions about the structures of human EFG1
and EFTu and about the effects of the human EFG1M496R
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Figure 5. Modeling of mitochondrial EFG1 (A and B) and EFTu (C and D). In panel A, the EFG1 GDP-binding site and the wild-type
M496 residue are indicated. In panel B, the pocket containing the M496 of EFG1 is magnified, and acidic, basic, and apolar residues
are in red, blue, and gray, respectively. In panel C, the three domains and the Arg 339 residue of EFTu are labeled. In panel D, the
model structure of human EFTu/tRNA complex is shown. The complex was obtained by superposing the bovine EFTu model on the crystal
structure of the EFTu/tRNA complex of T. aquaticus (PDB 1TTT). The tRNA structure is in blue. The binding site for tRNA is magnified;
note the position of the R339 residue, which is labeled for clarity.
and EFTuR339Q missense mutations, we took advantage of
information on the crystal structure of these proteins
available for a mammalian organism, B. taurus (NCBI ac-
cession number NP_776632), and a micro-organism, Ther-
mus aquaticus (NCBI accession number CAA46998).
Like other translocases, EFG1 is a single polypeptide
with a molecular weight of ∼80 kDa. As shown in figure
5A, the EFG1M496R mutation is located at the end of an a-
helix and before a b-sheet, in domain III of the mam-
malian protein.29 Detailed analysis of this region, a pocket
filled with both polar and apolar residues (fig. 5B), suggests
that a direct effect of the M496R amino acid substitution
on the EFG1 GTPase hydrolytic activity is unlikely, be-
cause the region is far from the GTP-binding site (fig. 5A).
Rather, the replacement of the smaller, hydrophobic/neg-
atively charged wild-type M with a bulkier, positively
charged R residue is likely to produce a drastic structural
rearrangement of the region that could, in turn, determine
the destabilization of the entire protein or impede its cor-
rect interaction with the ribosome.
Human EFTu is also a GTPase consisting of a single poly-
peptide of ∼45 kDa. The EFTuR339Q mutation is located on
a solvent-exposed b-sheet on the outer surface of domain
II of mammalian EFTu30 (fig. 5C). This position makes it
unlikely that the R339Q mutation can determine a drastic
structural rearrangement of the protein, because the in-
teraction with neighboring amino acid residues is mini-
mal. However, domain II constitutes the tRNA-bindingsite
of EFTu31 (fig. 5D); therefore, the most probable effect of
the R339Q substitution is to hamper the formation of the
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Figure 6. A, Tetrads analysis of MEF1/Dmef1 diploid transformed with MEF1wt or mef1M516R alleles. The relevant genotype of the diploid
strains is indicated on the left. One tetrad for the wild-type MEF1/Dmef1//MEF1wt transformant and three tetrads for the mutant MEF1/
Dmef1//mef1M516R transformant are shown. Spore clones from the same tetrads are displayed horizontally (a–d). Since deletion of the
MEF1 gene was created by insertion of the kanMX4 gene, which confers resistance to G418, the Dmef1 genotype is deduced by the
ability to grow on yeast peptone dextrose medium (YPD) supplemented with G418. Since the genetic background is Dura3 and the
plasmid pFL38 used for all constructs carries the URA3 wild-type allele, its presence is deduced by the ability to grow in the absence
of uracil. A respiratory-proficient phenotype is deduced by the ability to grow on glycerol (Gly) and ethanol (EtOH). Black squares
indicate the Dmef1 haploid strains transformed with the wild-type MEF1wt gene. Black circles indicate the Dmef1 haploid strains
transformed with the mef1M516R mutant allele. B, Tetrads analysis of TUF1/Dtuf1 diploid transformed with TUF1wt or tuf1R328Q alleles. The
relevant genotype of the diploid strains is indicated on the left. The same experimental scheme described above for MEF1 was applied
to TUF1. Black squares indicate the Dtuf1 haploid strains transformed with the wild-type TUF1wt gene. Black circles indicate the Dtuf1
haploid strains transformed with the tuf1R328Q mutant allele. C, Oxidative growth phenotype in TUF1 strains. Relevant genotype of the
haploid Dtuf1 strains is indicated on the left. Rows 2b, 2d, and 3d refer to the corresponding spores reported in panel B. Equal amounts
of serial dilutions of cells from exponentially grown cultures (105, 104, 103, and 102 cells) were spotted onto YP plates supplemented
with 3% Gly or 2% EtOH. The growth was scored after 2 d of incubation at 28C.
GTP:EFTu:aminoacyl-tRNA ternary complex. This hypoth-
esis is supported by the demonstration that the amount
and electrophoretic mobility of EFTuR339Q are both normal
(fig. 4).
Complementation Studies in Yeast
To validate the pathogenic role of the missense mutations
in mitochondrial EFG1 and EFTu in vivo, we set up ad
hoc recombinant systems in the budding yeast Saccharo-
myces cerevisiae, a facultative aerobic organism. MEF1 and
TUF1 are the yeast genes that encoded the orthologs of
human mitochondrial EFG1 and EFTu. Mutant versions
of these orthologs were expressed in null strains for each
gene.
Inactivation of MEF1 causes deletions in mtDNA that
give rise to petite mutants.32,33 Since the loss of a full-size
mitochondrial genome is an irreversible process, mutant
strains were obtained by sporulation and tetrad dissection
of a heterozygous diploid MEF1/Dmef1 strain transformed
with either wild-type MEF1 (MEF1wt) or with mutant
mef1M516R alleles. The mef1M516R mutation in yeast corre-
sponds to the EFG1M496R mutation in humans. Diploid
transformant clones will hereafter be indicated as MEF1/
Dmef1//MEF1wt and MEF1/Dmef1//mef1M516R. Likewise, a
diploid TUF1/Dtuf1 r strain was transformed with either
wild-type TUF1 (TUF1wt) or mutant tuf1R328Q alleles, with
tuf1R328Q the yeast mutation corresponding to the EFTuR339Q
human mutation. Diploid clones will be indicated as
TUF1/Dtuf1//TUF1wt and TUF1/Dtuf1//tuf1R328Q, respectively.
In the haploid transformant Dmef1//mef1M516R, obtained
from tetrad dissection, the mutant mef1M516R allele was
completely unable to complement the oxidative growth
defect of the Dmef1 strain (fig. 6A). In addition, the cy-
tochrome spectrum profile of the Dmef1 and Dmef1/
mef1M516R strains consistently lacked the peaks specific to
cytochromes b and aa3, which are part of the mtDNA-
dependent MRC complexes cIII and cIV, whereas the peak
specific to cytochrome c, a nucleus-encoded protein, was
normal (fig. 7A).
When the haploid transformant Dmef1//mef1M516R was
grown on glucose-containing medium for three cycles,
corresponding to ∼25 generations, the percentage of re-
spiratory-deficient (RD) mutant clones increased to vir-
tually 100% (data not shown). The petite mutants can be
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Figure 7. Reduced versus oxidized cytochrome spectra of MEF1 (A) and TUF1 (B) strains. The peak at 550 nm refers to cytochrome
c, the peak at 560 nm refers to cytochrome b, and the peak at 602 nm refers to cytochrome aa3. The cytochrome amount is proportional
to the height of the corresponding peak, relative to the baseline of each spectrum.
either r or r. The r mutants contain deletion-carrying
mtDNA, whereas r mutants are mtDNA-less mutants. To
evaluate the nature of the petite mutations (r vs. r), we
characterized mtDNA by Southern-blot analysis on RD
clones carrying the mef1M516R allele. Six of the eight clones
were devoid of mtDNA, whereas two displayed rearranged
mtDNA, indicating that the pathologic allele induced
prevalently r mutations (not shown).
Similar to MEF1, the inactivation of the TUF1 gene
causes deletions in mtDNA, giving rise to petite mutants.32
In the transformantDtuf1//tuf1R328Q strain, the tuf1R328Q mu-
tant allele partially complemented the oxidative growth
defect of the Dtuf1 strain (fig. 6B and 6C). To evaluate
whether the tuf1R328Q mutation affected mtDNA stability,
we measured the frequency of petite mutants in haploid
Dtuf1 strains carrying either the tuf1R328Q or the TUF1wt
allele. In the Dtuf1// tuf1R328Q strain, the petite frequency
was indistinguishable from that of the Dtuf1// TUF1strain
(data not shown), indicating that the mutation did not
affect mtDNA stability. The cytochrome spectrum profile
of the Dtuf1 strain lacked both cytochrome b and aa3
peaks. The Dtuf1/tuf1R328Q strain showed the virtual ab-
sence of the peak corresponding to cytochrome aa3 but a
less profound reduction of the peak corresponding to cy-
tochrome b (fig. 7B). In both strains, the peak specific to
cytochrome c was normal.
In MEF1/Dmef1//mef1M516R and TUF1/Dtuf1//tuf1R328Q
heteroallelic diploid strains, oxidative growth and cyto-
chrome profiles were similar to those of the wild-type hap-
loid strains, indicating that both mutations behave as re-
cessive traits in yeast, like the corresponding mutations
do in humans.
Complementation Studies in Fibroblasts
To establish the specific role of the EFG1M496R mutation in
determining the OXPHOS-defective phenotype observed
in mutant cells, we expressed recombinant wild-type EFG1
(EFG1wt) in an immortalized fibroblast cell line derived
from patient I.V. Figure 8A shows the histochemical re-
covery of COX activity obtained in this cell line, compared
with the profound COX defect of the parental culture.
This result was confirmed by biochemical assay of MRC
complexes cI and cIV in cell homogenate (fig. 8B). As
shown in figure 8, we found a several-fold increase in the
activities of transfected fibroblasts relative to the untrans-
fected original cultures; this recovery reached ∼80% for cI
activity and ∼40% for cIV activity, relative to the control
mean. The histochemical and biochemical rescue was
accompanied by recovery of mtDNA-specific translation
(fig. 9). Similar results—consisting of histochemical COX
recovery (fig. 8A); biochemical recovery of 79% for cI
and 34% for cIV, relative to the control mean (fig. 8B);
and clear recovery of mitochondrial protein translation
(fig. 9)—were obtained by re-expressing wild-type EFTu
(EFTuwt) in immortalized fibroblasts from patient S.S. How-
ever, functional complementation occurred in EFTuR339Q
mutant cells transfected with EFTuwt only when they were
exposed for at least 1 d to a medium containing galactose
instead of glucose as the major carbon source, whereas
cells that were not treated with the galactose-containing
medium failed to show any functional rescue, either in
the activities of cI and cIV (fig. 8A and 8B) or in mito-
chondrial protein synthesis (fig. 9). The possibility that
this result was because of a lack of expression of the EFTuwt
recombinant cDNA in transfected cells of patient S.S. was
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Figure 8. Complementation analysis in fibroblasts to determine histochemical and biochemical activities. A, COX-specific cytochemical
reaction in immortalized fibroblasts cells from patients I.V. and S.S. and in the same cells after transfection with vectors expressing
EFG1wt and EFTuwt, grown in DMEM glucose medium, or after exposure for 1 d to DMEM galactose medium. B, Biochemical activities of
cI and cIV in immortalized fibroblasts from patients I.V. and S.S. An asterisk (*) indicates Student’s t test ; a double asteriskP ! .05
(**) indicates . Statistical analysis was performed when four or more values were available for each category.P ! .01
excluded by sequence analysis of retrotranscribed EFTu
RNA, which showed the presence of both the wild-type
and the mutant RNA species in an ∼1:1 ratio (not shown).
In contrast to glucose, galactose is a predominantly aer-
obic source of energy and is, in fact, used in selective me-
dium to eliminate OXPHOS-incompetent mammalian
cells. For instance, the OXPHOS-defective EFTuR339Q mu-
tant cells, which either were not transfected or were trans-
fected with an “empty” vector, all died after overnight
exposure to the galactose selection medium (not shown).
Complementation Studies in Cell Hybrids and Cybrids
To further explore the unexpected behavior of EFTuR339Q
mutant cells, we performed a series of experiments on
hybrids generated by fusion of immortalized fibroblasts
from our patients with a mtDNA-less 143B r cell line.
Selectable markers were exploited to obtain heterodikar-
yon cells—that is, hybrids derived from two cells of dif-
ferent parental origin (see the “Material and Methods”
section)—which were confirmed by genotyping with suit-
able, highly polymorphic DNA markers (not shown). Fu-
sions of EFG1M496R defective cells with 143B r cells showed
the prompt recovery of robust histochemical (fig. 10A) and
biochemical (fig. 10B) COX activity. However, when we
repeated the same experiment, using the EFTuR339Q defec-
tive cell line, we observed neither histochemical nor bi-
ochemical recovery of COX activity (fig. 10A and 10B).
Robust recovery of COX activity was documented in trans-
mitochondrial cybrids derived from the fusion of 143B r
cells with cytoplasts from fibroblasts of patient S.S. (fig.
10A and 10B). Together with the data on mtDNA sequence
analysis, this result further confirms that the biochemical
and clinical phenotype of patient S.S. was not due to a
primary defect of her mtDNA.
Discussion
Mitochondrial EFG1 is a five-domain GTPase, which cat-
alyzes the translocation step of protein biosynthesis—that
is, the movement of the peptidyl-tRNA-mRNA complex
on the ribosome during protein elongation. This process
consists in the transfer of the nascent peptidyl-tRNA from
the ribosomal acceptor (amino acyl or A) site to the ri-
bosomal peptidyl site and the consequent removal of an
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Figure 9. Complementation analysis in fibroblasts to determine mitochondrial protein synthesis. pCDNA3 indicates fibroblasts trans-
fected with the pCDNA3 “empty” vector (no insert), EFG1wt and EFTuwt indicate fibroblasts transfected with vectors expressing the
corresponding wild-type proteins, and Gal refers to fibroblasts exposed to galactose-containing medium. The bands are labeled as in
figure 2.
uncharged tRNA from the peptidyl site to the ribosomal
exit site.34
Patient I.V. was a compound heterozygote for two novel
EFG1 mutations: a stop mutation, which predicts the syn-
thesis of a 46-aa polypeptide, and a missense mutation in
a highly conserved amino acid residue of EFG1 domain
III. The first reported EFG1-mutant patients were affected
by severe neonatal liver failure.7,8 In one patient, inves-
tigated by Antonicka et al.,8 the EFG1 protein was unde-
tectable in the liver, was very low in muscle and fibro-
blasts, but was only 60% lower than control levels in heart,
thus paralleling the severity of the observed OXPHOS de-
fect and organ failure. EFG1 expression in normal liver
was found to be lower than in other tissues, again pro-
viding a possible explanation for the observed tissue spec-
ificity of the syndrome. No data are available concerning
the expression of mitochondrial EFG1 in human brain,
but the clinical features of our EFG1 mutant patient clearly
indicate a primary involvement of the CNS, which over-
whelmed, by far, that of other organs—notably, skeletal
muscle, liver, and heart. Our patient never had laboratory
or clinical signs of hepatic involvement. Her clinical
course was dominated by severe, neonatal lactic acidosis
and rapidly evolving neurological failure, with the neu-
roradiological hallmarks of early-onset Leigh syndrome—
namely, bilateral necrotizing lesions in the basal ganglia,
diencephalon, and brain stem.35 A number of hypotheses
can be formulated to explain these observations. For in-
stance, specific mutations in different regions of the same
EFG1 protein may have different effects on mitochondrial
translation in different tissues, thereby dictating the spe-
cific clinical outcome of different individuals. It is also
possible that adaptive mechanisms may act differently in
different patients, thereby contributing to the observed
clinical variability. This is the likely mechanism that could
explain the recently reported association of the same mu-
tation in mitochondrial EFTs with entirely distinct syn-
dromes: an encephalomyopathy and a cardiomyopathy.9
Another fact to be considered is that, in humans and other
organisms, including yeast, there are two alleged isoforms
of mitochondrial EFG—namely, EFG1 and EFG2—which
raises the possibility that a defect of the former protein
can be partly compensated by the activity of the latter,
possibly in a tissue- and individual-specific fashion. This
hypothesis is supported by the observation that human
EFG2 is highly expressed in energy-consuming tissues,
such as skeletal muscle, heart, and fetal liver, which con-
tain a large number of mitochondria.36 The functional role
of EFG2, however, is uncertain; for instance, the ablation
of yeast MEF2, the homolog of EFG2, is not associated
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Figure 10. Complementation analysis in cell hybrids and cybrids. A, COX-specific cytochemical reaction in immortalized fibroblast cells
from patients I.V. and S.S., 143B r cells, 143B progenitor cells, transmitochondrial cybrids, and heterodikaryon hybrids. B, Biochemical
activities of cIV in fibroblasts, 143B r cells, 143B progenitor cells, transmitochondrial cybrids, and heterodikaryon hybrids.
with an OXPHOS phenotype, as is the case for MEF1, the
homolog of EFG1, the ablation of which causes an ex-
tremely drastic petite r phenotype.
Our second patient, S.S., carried the first mutation ever
reported in mitochondrial EFTu (R339Q). Like EFG1, EFTu
is a GTPase. The GTP:EFTu activated complex loads an
aminoacyl-tRNA from its specific transferase, escorts it to
the ribosomal A site, and is then released from the ribo-
some as an EFTu:GDP inactive complex. This complex is
the substrate of EFTs, which promotes the exchange of
GDP with GTP on EFTu, thus reactivating it. Patient S.S.
had an extremely severe syndrome, dominated by lactic
acidosis and rapidly fatal encephalopathy, with diffuse
cystic leukodystrophy and micropolygyria, a developmen-
tal abnormality of the brain that occurs well before birth.
Modest elevation of hepatic enzymes in blood and epi-
sodic hyperammonemia indicated mild liver involvement
that never progressed into hepatic failure. Other tissues,
notably the heart, were clinically spared. The identifica-
tion of other patients with mutations will show to what
extent the brain abnormalities of our patient S.S. are spe-
cific to EFTu mutation.
The deleterious effects of the mutations on mitochon-
drial EFG1 and EFTu were predicted by modeling studies
on their crystal structures, and their consequences for OX-
PHOS were validated by functional studies in both yeast
and mammalian recombinant systems. The missense mu-
tations found in our patients hit amino acid residues that
are conserved from mammals to the facultative aerobic
yeast S. cerevisiae (fig. 4).
The MEF1-defective yeast strain (Dmef1) displays an OX-
PHOS phenotype characterized by failure to grow in media
containing glycerol, ethanol, or other obligatory aerobic
compounds as the only carbon sources. No correction was
obtained by re-expressing, in the Dmef1 strain, a mef1 var-
iant harboring mef1M516R, a mutation equivalent to human
EFG1M496R. The OXPHOS phenotype of the Dmef1 strain is
associated with mtDNA instability, which, in turn, deter-
mines increased segregation of RD petite mutants.37 When
the Dmef1 strain re-expressing the mef1M516R mutant allele
was grown in a glucose-containing medium, it produced
virtually 100% RD mutant clones, indicating, for this mu-
tation, a nearly complete loss of function. Taken together,
these results indicate that the EFG1 mutation found in
humans is deleterious in yeast.
The yeast tuf1R328Q, equivalent to human EFTuR339Q, gave
a clearly defective OXPHOS phenotype, less drastic, how-
ever, than that of the DTUF1 null strain, indicating the
preservation of some functional competency. In particu-
lar, aerobic growth was reduced but not abolished in the
Dtuf1// tuf1R328Q strain, and, although the decrease of cy-
tochrome aa3, which is part of COX, was marked, that of
cytochrome b, which is part of cIII, was much milder than
in the Dmef1 strain. It is interesting that the effects on
cytochrome content of the tuf1R328Q mutation are similar
to those produced by chloramphenicol, an inhibitor of
mitochondrial protein synthesis.38 The “leaky” phenotype
observed in yeast is in contrast to the extremely severe
biochemical and translational defects found in EFTuR339Q
human mitochondria. A possible explanation for this dis-
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crepancy is that the orthology of yeast tuf1 to mammalian
EFTu is imperfect, because the former combines, in a single
polypeptide, the functions of both EFTu and EFTs.
In complementation experiments performed on mam-
malian cell cultures, we observed that the multiple defects
of MRC activities and the profound decrease of mtDNA
translation were both corrected by re-expression of either
EFG1wt or EFTuwt in the corresponding mutant fibroblast
cell lines. These results confirm the pathogenic role of the
EFG1M496R and EFTuR339Q mutant alleles in causing OX-
PHOS failure and disease. However, in contrast to the
EFG1wt-transfected EFG1M496R mutant cells, the phenotype
rescue of the EFTuwt-transfected EFTuR339Q mutant cells was
obtained only by use of a strictly aerobic growth medium,
which selects cells for OXPHOS competency. This result
was confirmed by the persistence of faulty COX activity
in heterodikaryon hybrids obtained by fusion of EFTuR339Q
mutant cells and 143B r cells, whereas the hybrids be-
tween EFG1M496R and 143B r cells had nearly normal COX
activity.
The refractoriness of EFTuR339Q mutant cells to functional
complementation remains unexplained. One possibility is
the coexistence of a syn mutation in mtDNA, but it was
excluded by sequencing of the entire mtDNA of patient
S.S. However, several other hypotheses can be formulated
to explain this unexpected behavior. For instance, the
EFTuR339Q could exert a dominant negative effect in cell
culture, which is compatible with the persistence of the
mutant protein in fibroblasts (fig. 4) but is baffling for a
genetic defect that is clearly recessive in carriers and af-
fected individuals. A second possibility is that the OX-
PHOS rescue could be limited by the relative amount of
EFTs compared with EFTu, as suggested by the leaky phe-
notype of the Dtuf1//tuf1R328Q mutant yeast strain. A third
possibility is that EFTuwt itself could inhibit translation
when overexpressed, as recently proposed for both EFTu8
and EFTs.9
Future work is warranted to challenge these hypothe-
ses—for instance, by titration of the expression of recom-
binant EFTuR339Q or EFTuwt in normal cells and by coex-
pression of recombinant EFTuwt and EFTswt in EFTuR339Q
mutant cells.
The two patients described here were part of a cohort
of six infantile cases with a common biochemical signa-
ture: multiple MRC defects in muscle and cultured fibro-
blasts. Of the four remaining patients, two brothers af-
fected by MLASA had a homozygous mutation in PUS1,39
whereas the other two involve cases that are still unde-
fined at the molecular level. Although limited in number,
these observations and similar findings recently reported
by others4,6–9 contribute to define a new, rapidly expanding
group of nuclear gene defects that could account for a
substantial fraction of mitochondrial disorders of infancy
and childhood. In addition, these results reveal the exis-
tence of complex, and partly unexpected, checkpoint
mechanisms regulating mtDNA protein synthesis. The
elucidation of these mechanisms can help us understand
the biology of mtDNA homeostasis and the pathophysi-
ology of its defects.
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Accession numbers and URLs for data presented herein are as
follows:
ClustalW, http://www.ebi.ac.uk/clustalw/
Euroscarf, http://web.uni-frankfurt.de/fb15/mikro/euroscarf/
Mitomap, http://www.mitomap.org/
NCBI, http://www.ncbi.nlm.nih.gov/ (for EFG1 H. sapiens [ac-
cession number Q96RP9], M. musculus [accession number
Q8K0D5], D. melanogaster [accession number Q9VM33], C. ele-
gans [accession number Q9XV52], and S. cerevisiae [accession
number P25039] and EFTu H. sapiens [accession number
P49411], M. musculus [accession number Q8BFR5], B. taurus [ac-
cession number NP_776632], D. melanogaster [accession num-
ber Q86NS6], C. elegans [accession number P02992], S. cerevisiae
[accession number Q19072], and T. aquaticus [accession num-
ber CAA46998])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for MLASA, MRPS16, and combined ox-
idative phosphorylation deficiency 1)
PDB, http://www.rcsb.org/pdb
RZPD German Resource Center, http://www.rzpd.de/
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